Comparative Pharmacology
Head-to-head clinical analysis: AMBIEN CR versus DORIDEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBIEN CR versus DORIDEN.
AMBIEN CR vs DORIDEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBIEN CR's active ingredient is zolpidem, a non-benzodiazepine hypnotic that binds selectively to the benzodiazepine-1 (BZ1) receptor subtype on the GABA-A receptor complex, potentiating GABAergic inhibition and promoting sleep.
Barbiturate-like sedative-hypnotic; acts on GABA-A receptors to enhance inhibitory neurotransmission, causing CNS depression.
12.5 mg orally once daily immediately before bedtime; lower dose of 6.25 mg may be considered. Not to exceed 12.5 mg per day.
500 mg orally at bedtime, maximum 1 g per day; for sedation, 250 mg 3 times daily after meals.
None Documented
None Documented
Zolpidem immediate-release: ~2.5 h (range 1.4–3.8 h); modified-release (Ambien CR): ~2.8 h (range 1.6–4.5 h). Clinical note: Half-life increased in hepatic impairment and elderly.
Terminal elimination half-life is 4-10 hours in healthy adults; prolonged in elderly and patients with hepatic impairment, increasing to 12-20 hours.
Primarily renal (80% as metabolites, <5% unchanged), minor fecal (<10%)
Renal (accounting for approximately 80% of elimination, primarily as glucuronide conjugates and unchanged drug); biliary/fecal (minor, about 10%).
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic